Oral Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2018

The NOMINATOR Trial – panel testing in the Australian Context (#63)

Clare Scott 1
  1. Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia

The NOMINATOR study, Genomic Matching Treatment for Rare Cancers, opened in July 2017 as a feasibility study of performing genomic testing of rare cancers to match the cancer to treatment. This clinical pilot study intended to accrue 100 patients over two years and was the first national study to facilitate access for rare cancer patients to novel tumour genomic analysis using the Petermac Comprehensive Cancer Panel in an attempt to match their cancer to therapy. The aim was to provide guidance for their doctors regarding treatment choices targeted to their cancer. Patient involvement in the NOMINATOR study is limited to those patients who might benefit from treatment-direction and who have a rare cancer type about which very little is known. To date 56 patients have been recruited, 16 in Melbourne, 8 in Adelaide, 8 in Perth and 24 in Brisbane (in Sydney patients were recruited to the MoST trial instead). The tumor types and impact on treatment will be presented.